At a glance
ClinicalIndex Comparison Record- ✓Stage 3a, 3b, or 4 chronic kidney disease
- ✓Age ≥18 years
- ✓Normal serum phosphate (≤4.6 mg/dL)
- ✕Rapidly advancing renal failure or high risk of ESRD/dialysis initiation during study
- ✕Expected to require dialysis within follow-up period
- ✕Hyperphosphatemia >4.6 mg/dL
- ✕Prior or current phosphate binder or active vitamin D (doxercalciferol or calcitriol) therapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Fibroblast Growth Factor-23 Reduction in Predialysis Chronic Kidney Disease
In Brief
A clinical study evaluating Lanthanum Carbonate, 900 mg Phosphate Diet, and 2 other interventions for Kidney Disease. Completed, enrolled 43 participants across 1 site.
Detailed Summary
The investigators would like to study the role of phosphorus metabolism in the development of certain hormonal problems in people with chronic kidney disease (CKD). More specifically, the goals of the research are (1) to understand the cause of hyperparathyroidism - a hormone problem that often develops in patients who have kidney disease and (2) to test whether decreasing phosphorus intake could help improve or prevent hyperparathyroidism.
Study Details
Timeline
Interventions
Phosphorus binder
Amount of phosphorus consumption in a day kept below 900 mg.
Placebo for Lanthanum Carbonate
Patients continued to eat their usual diet.